Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
m |
m |
||
| Line 2: | Line 2: | ||
Thrombopoietin receptor agonist | Thrombopoietin receptor agonist | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Autoimmune thrombocytopenic purpura (ITP)]] | |
# Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. [http://bloodjournal.hematologylibrary.org/content/123/25/3887.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24802775 PubMed] | # Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. [http://bloodjournal.hematologylibrary.org/content/123/25/3887.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24802775 PubMed] | ||
| + | *[[Thrombocytopenia in liver disease]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 5/21/2018: FDA approved "for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] scheduled to undergo a procedure." | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' YM477, AKR 501 | + | *'''Code names:''' E5501, YM477, AKR 501 |
| + | *'''Brand name:''' Doptelet | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 17: | Line 22: | ||
[[Category:Immune thrombocytopenic purpura (ITP) medications]] | [[Category:Immune thrombocytopenic purpura (ITP) medications]] | ||
| − | [[Category: | + | [[Category:Drugs FDA approved in 2018]] |
Revision as of 18:37, 21 May 2018
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is used
- Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, Tang S, McIntosh J. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014 Jun 19;123(25):3887-94. Epub 2014 May 6. link to original article PubMed
History of changes in FDA indication
- 5/21/2018: FDA approved "for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure."
Also known as
- Code names: E5501, YM477, AKR 501
- Brand name: Doptelet